Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.
Wrighton
S A
SA
Department of Drug Metabolism and Disposition, Lilly Corporate Center, Indianapolis, Indiana 46285.
Ring
B J
BJ
D002851:Chromatography, High Pressure Liquid; D002927:Cimetidine / Q000494:pharmacology*; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007654:Ketoconazole / Q000494:pharmacology*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D008874:Midazolam / Q000031:analogs & derivatives* / Q000378:metabolism; D009543:Nifedipine / Q000494:pharmacology*; D016567:Nizatidine / Q000494:pharmacology*
D065607:Cytochrome P-450 Enzyme Inhibitors; D004917:Erythromycin; D002927:Cimetidine; D003577:Cytochrome P-450 Enzyme System; C040081:1-hydroxymethylmidazolam; D009543:Nifedipine; D016567:Nizatidine; D008874:Midazolam; D007654:Ketoconazole